Referring patients with chronic kidney disease back to primary care: a criteria-based analysis in outpatient renal clinics

Carola van Dipten, Davy Gerda Hermina Antoin van Dam, Wilhelmus Joannes Carolus de Grauw, Marcus Antonius Gerard Jan ten Dam, Marcus Matheus Hendrik Hermans, Willem Jan Jozef Assendelft, Nynke Dorothea Scherpbier-de Haan and Jacobus Franciscus Maria Wetzels

Abstract

Background: The increased demand for nephrology care for patients with chronic kidney disease (CKD) necessitates a critical review of the need for secondary care facilities and the possibilities for referral back to primary care. This study aimed to evaluate the characteristics and numbers of patients who could potentially be referred back to primary care, using predefined criteria developed by nephrologists and general practitioners.

Method: We organised a consensus meeting with eight nephrologists and two general practitioners to define the back referral (BR) criteria, and performed a retrospective cohort study reviewing records from patients under nephrologist care in three hospitals.

Results: We reached a consensus about the BR criteria. Overall, 78 of the 300 patients (26%) in the outpatient clinics met the BR criteria. The characteristics of the patients who met the BR criteria were: 56.4% male, a median age of 70, an average of 3.0 outpatient visits per year, and a mean estimated glomerular filtration rate of 46 ml/min/1.73m². Hypertension was present in 67.9% of this group, while 27.3% had diabetes and 16.9% had cancer. The patients who could be referred back represented all CKD stages except stage G5. The most common stage (16%) was G3bA2 (eGFR 30 ≤ 44 and ACR 3 ≤ 30).

Conclusion: A substantial proportion of patients were eligible for referral back to primary care. These patients often have a comorbidity, such as hypertension or diabetes. Future research should focus on generalisability of the BR criteria, the feasibility of actual implementation of the back referral, follow-up assessments of renal function and patient satisfaction.

Keywords: Chronic kidney disease, Shared care, Back referral, Primary care, Retrospective cohort study

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Most patients with chronic kidney disease (CKD) have a mild to moderate CKD (stages 1–3), as classified according to the Kidney Outcomes Quality Initiative guidelines [1, 2]. Consequently, most patients with CKD can be treated by their general practitioner (GP). The Dutch CKD guideline for primary care [3], comparable to the National Institute for Health and Care Excellence guidelines in the UK [4], provides GPs with tools for diagnostics, monitoring and treatment. Also, this guideline clearly defines the criteria for consultation with, or referral to, secondary care providers; for instance, in the case of a rapid decline in the glomerular filtration rate or severe proteinuria, the GP should refer the patient to, or at least consult, a nephrologist. Timely referrals have been repeatedly shown to affect outcome measures, such as mortality and reaching end-stage renal failure [5], and are essential when a requirement for renal replacement therapy is indicated.

The rising prevalence and incidence of CKD will increase the number of referrals made to nephrology practitioners [6–8], increasing healthcare costs and posing a burden for both patients and nephrologists [9, 10]. However, it is questionable whether many of the referred patients with CKD actually need long-term care from a nephrologist. Patients with stable CKD could be referred back to primary care with the proper support [4]. The increased demand for hospital care necessitates a periodical, broadly supported, criteria-based critical review of patients in secondary care facilities, together with an evaluation of the possibilities for referral back to primary care where possible.

Remarkably, none of the above-mentioned guidelines clearly indicate when patients can or should be referred back to primary care, nor, to the best of our knowledge, have any studies investigated the proportion and characteristics of patients who might be eligible. The aim of this study was therefore to develop criteria for referral from secondary care back to primary care, and to evaluate the characteristics and the number of patients who could be eligible for back referral.

Materials and methods
Development of criteria for referral back to primary care
To define the back referral criteria (BR criteria) for discharging patients with CKD to primary care, we organised a consensus meeting with eight nephrologists from different hospitals in the south-east of the Netherlands and two GPs, both members of the national CKD guideline committee (see names and hospitals or practices in acknowledgements and author contributions). In this meeting, we also defined which patients could not be referred back to primary care. A summary of the meeting was circulated among the participants for feedback, and a consensus document was made. The BR criteria were returned to all participants for checking, and were accepted by all.

Proportion and characteristics of patients who fulfilled the BR criteria
Study setting
In a retrospective cohort study, we reviewed the records of patients under nephrologist care in three hospitals (VieCurie Medical Center (VMC) in Venlo, and Canisius Wilhelmina Hospital (CWH) and Radboud university medical center (RUMC) in Nijmegen). We recruited participants at the outpatient clinics because hospitalized patients are by definition not stable. Patients were included for their kidney disease, regardless of the aetiology. Also, patients requiring follow-up after hospitalization, patients with a history of acute kidney injury or previous kidney transplantation were included. Patients visiting the renal clinics were informed about the study, and their informed consent was obtained prior to their participation. There were no exclusion criteria. Patients were recruited by all nephrologists in the participating renal clinics. The recruitment period lasted until about 100 patients per clinic were included. This study is an exploration of back referral criteria and the number of potential patients eligible for referral back. For this, the patients were not actually referred back to primary care.

Data collection and analysis
The researchers ( CvD, resident in general practice and PhD candidate in CKD in primary care, and DvD, resident in internal medicine) extracted the patient demographics and clinical data from the medical records. The authorised web-based system Castor was used for data collection and storage. This system enables researchers to build electronic Case Report Forms and store data [11]. The researchers completed a standard form for each patient, then checked whether the patient met the BR criteria. A patient’s nephrologist was consulted by the researchers in the following cases: doubts about the back referral; a lack of clarity in the patient’s medical file; if the CKD was stable but was caused by a specific nephrological disease; and when the researchers found notes about a back referral in the medical file despite the patient not meeting the BR criteria. We used descriptive statistics (SPSS version 25) to assess the patients’ characteristics and the proportion of patients with CKD who could be referred back to primary care. We used chi-square tests and independent-sample t-tests to assess the statistical significance of the results. In the case of non-normal distributions, we used Mann Whitney U-tests to evaluate statistical significance. A P-value < 0.05 was considered significant.
Results
The following BR criteria were defined:

- Patients with stable kidney function **AND** stable blood pressure **AND** stable metabolic parameters, in whom renal replacement therapy is not expected within five years (for definitions, see textbox).
- Patients with haematuria and/or proteinuria less than 1 g/24 h **AND** with stable kidney function **AND** stable blood pressure. Exception: patients with IgA nephropathy who are eligible (now or in the future) for immunosuppressive therapy.
- Patients not eligible for renal replacement therapy (because of comorbidity, age or patient preference), provided that the patient’s kidney function and metabolic parameters are stable.

**Stable kidney function**: a decrease in estimated glomerular filtration rate (eGFR) less than

1a) ≥25% compared to the first measurement within five years **OR** 1b) ≤5 ml/min/1.73 m²/year

**Stable blood pressure**: patients with a stable blood pressure at or below their individual target value and without drug adjustments in the last two consultations.

**Stable metabolic parameters**: patients without medication changes concerning phosphate, calcium, parathormone or haemoglobin in the last two consultations.

In addition, we defined the criteria for patients who should not be referred back to primary care:

- Patients with a rapid decrease of kidney function, defined as a drop in eGFR of more than 5 ml/min/1.73 m²/year **OR** a decrease of more than 25% in five years.
- Patients with proteinuria of more than 1 g/24 h.
- Patients with an eGFR less than 30 ml/min/1.73 m², showing progression and with reasonable to good physical health, who would be eligible for renal replacement therapy.
- Patients expected to require renal replacement therapy within five years.
- Patients using immune suppressive drugs in the context of a renal disease or after a kidney transplant.
- Patients with specific nephrological diseases with a risk of relapse or a high risk of disease progression, such as patients with polycystic kidney disease or patients with lupus nephritis.

**Study population and patients fulfilling the BR criteria**

The study was conducted between February and September 2018. We included a total of 300 patients: 102 patients from CWH, 100 patients from VMC and 98 patients from RUMC. Of those, 57.5% were male, the median age was 67.5 years and the average number of outpatient visits was 3.8 times a year. The average eGFR was 42 ml/min/1.73m², and most patients had moderate albuminuria. Hypertension (60%), diabetes mellitus (24.7%) and cancer (unspecified) (19.7%) were the most common comorbidities. Glomerular pathology was the most common aetiology for CKD (see Table 1).

Overall, 78 of the 300 patients (26%) in the outpatient clinics met the BR criteria (see Fig. 1), varying between 23 and 30% per clinic. Of the patients who met the BR criteria, 56.4% were male, and their median age was 70 years (see Table 1). Their average monitoring frequency was lower (3.0 vs. 4.1 times per year, \(P = 0.000\)) and their mean eGFR was higher (46 vs. 40 ml/min/1.73m², \(P = 0.044\)) than the patients who did not meet the BR criteria. Patients who met the BR criteria more often had heart failure (19.2% vs. 7.8%, \(P = 0.007\)) and had suffered a transient ischaemic accident (TIA) or a cerebrovascular accident (CVA) (21.8% vs. 10.8%, \(P = 0.018\)), but less commonly had cancer (16.9% vs. 20.8%, \(P = 0.042\)). Patients eligible for referral back to primary care were classified into all CKD stages, most commonly into stages G3bA2 (16%) and G4A2 (14.1%) (see Table 2).

**Discussion**

**Summary of the main findings**

When applying the BR criteria to the records of patients at the renal clinics, the proportion of patients with CKD who could be referred back to primary care varied between 23 and 30% per clinic. In addition, several patients seemed to be potential candidates for a future back referral, such as patients with stable CKD but who currently had too short of a follow-up period, or patients who had recently changed their blood pressure medication because of side effects rather than problems.
Table 1 Characteristics of all patients in the renal clinics, and a comparison between those who were and were not considered eligible for referral back (BR) to primary care.

|                                           | All patients N = 300 | Patients meeting the BR criteria N = 78 (26%) | Patients not meeting BR criteria N = 222 (74%) | P-value |
|-------------------------------------------|----------------------|-----------------------------------------------|-----------------------------------------------|---------|
| **Demographics patients**                 |                      |                                               |                                               |         |
| Gender, male (%)                          | 173 (57.5%)          | 44 (56.4%)                                    | 129 (58.1%)                                  | 0.794   |
| Age in years, median (range)              | 67.5 (19–96)         | 70 (25–88)                                    | 67 (19–96)                                   | 0.265   |
| Number of outpatient visits, mean         | 3.8 ± 1.66           | 3.0 ± 1.28                                    | 4.1 ± 1.69                                   | < 0.001 |
| **Aetiology**                             |                      |                                               |                                               |         |
| ADPKD*                                    | 33/300 (11.0%)       | 7/78 (9.0%)                                   | 26/222 (11.7%)                               | 0.506   |
| Glomerular diseases¹                       | 82/300 (27.3%)       | 18/78 (23.1%)                                 | 64/222 (28.8%)                               | 0.327   |
| Systemic diseases²                        | 20/300 (6.7%)        | 0/78 (0.0%)                                   | 20/222 (9.0%)                                | 0.006   |
| Tubulointerstitial nephritis              | 11/300 (3.7%)        | 2/78 (2.6%)                                   | 9/222 (4.1%)                                 | 0.547   |
| Drug-induced CKD                          | 7/300 (2.3%)         | 2/78 (2.6%)                                   | 5/222 (2.3%)                                 | 0.875   |
| Vascular CKD                              | 61/300 (20.3%)       | 19/78 (24.4%)                                 | 42/222 (18.9%)                               | 0.304   |
| Diabetic nephropathy                      | 26/300 (8.7%)        | 8/78 (10.3%)                                  | 18/222 (8.1%)                                | 0.562   |
| Other cause                 | 38/300 (12.7%)       | 11/78 (14.1%)                                 | 27/222 (12.2%)                               | 0.658   |
| Unknown cause                            | 20/300 (6.7%)        | 11/78 (14.1%)                                 | 9/222 (4.1%)                                 | 0.002   |
| **Measurements**                          |                      |                                               |                                               |         |
| eGFR (ml/min/1.73²), mean                | 42 ± 21.07           | 46 ± 19.95                                    | 40 ± 21.3                                    | 0.044   |
| Stage proteinuria, (%)                   |                      |                                               |                                               | 0.007   |
| A1                                        | 47/206 (15.9%)       | 15/78 (19.2%)                                 | 32/218 (14.7%)                               |         |
| A2                                        | 121/206 (40.9%)      | 41/78 (52.6%)                                 | 80/218 (36.7%)                               |         |
| A3                                        | 128/206 (43.2%)      | 22/78 (28.2%)                                 | 106/218 (48.6%)                              |         |
| Haemoglobin (g/dl), mean                 | 13.21 ± 1.79 (n = 253) | 13.54 ± 1.82 (n = 72) | 13.05 ± 1.77 (n = 181) | 0.054   |
| Potassium (mmol/L), mean                 | 4.5 ± 0.49 (n = 265) | 4.4 ± 0.39 (n = 78)                          | 4.5 ± 0.53 (n = 187)                         | 0.865   |
| Phosphate (mmol/L), mean                 | 1.05 ± 0.28 (n = 224) | 1.01 ± 0.29 (n = 63) | 1.06 ± 0.27 (n = 161) | 0.196   |
| Systolic blood pressure (mm Hg), mean    | 131 ± 166 (n = 283)  | 131 ± 164 (n = 76)                           | 131 ± 167 (n = 207)                          | 0.967   |
| Diastolic blood pressure (mm Hg), mean   | 73 ± 9.96 (n = 283)  | 74 ± 8.37 (n = 76)                           | 73 ± 10.48 (n = 207)                         | 0.424   |
| **Comorbidity**                           |                      |                                               |                                               |         |
| Angina pectoris                           | 33/271 (12.2%)       | 10/77 (13.0%)                                 | 23/194 (11.9%)                               | 0.797   |
| Myocardial infarction                     | 42/272 (15.4%)       | 16/78 (19.8%)                                 | 26/194 (13.4%)                               | 0.142   |
| Heart failure                             | 30 /270 (11.1%)      | 15/78 (19.2%)                                 | 15/192 (7.8%)                                | 0.007   |
| Hypertension (K86.87)                     | 180/274 (65.7%)      | 53/78 (67.9%)                                 | 127/196 (64.8%)                              | 0.620   |
| TIA or CVA                                | 38/272 (14.0%)       | 17/78 (21.8%)                                 | 21/194 (10.8%)                               | 0.018   |
| Hemiplegia                                | 0/271 (0%)           | 0/78 (0%)                                     | 0/193 (0%)                                   | NA      |
| Peripheral vascular disease               | 41/270 (15.2%)       | 9/77 (11.5%)                                  | 32/193 (16.6%)                               | 0.312   |
| Diabetes mellitus                         | 74/270 (27.4%)       | 21/77 (27.3%)                                 | 53/193 (27.5%)                               | 0.608   |
reaching their target values. The criteria were easily applicable and their use required little discussion. In only four cases, the judgments of the researchers and nephrologists overruled the BR criteria (for more detail see Fig. 1). Patients eligible for referral back to primary care represented all CKD stages except for stage G5, and did not differ much from the patients not eligible for back referral in terms of their demographics.

Table 1 Characteristics of all patients in the renal clinics, and a comparison between those who were and were not considered eligible for referral back (BR) to primary care. (Continued)

|                      | All patients N = 300 | Patients meeting the BR criteria N = 78 (26%) | Patients not meeting BR criteria N = 222 (74%) | P-value |
|----------------------|----------------------|---------------------------------------------|---------------------------------------------|---------|
| **Uncomplicated**    |                      |                                             |                                             |         |
|                      | 35/270 (13.0%)       | 8/77 (10.4%)                                | 27/193 (14.0%)                              |         |
| **Complicated**      |                      |                                             |                                             |         |
|                      | 39/270 (14.4%)       | 13/77 (16.9%)                               | 26/193 (13.5%)                              |         |
| **COPD**             |                      |                                             |                                             |         |
|                      | 20/272 (7.4%)        | 6/78 (7.7%)                                 | 14/194 (7.2%)                               | 0.892   |
| **Dementia**         |                      |                                             |                                             |         |
|                      | 0/272 (0%)           | 0/78 (0%)                                   | 0/194 (0%)                                 | NA      |
| **Liver disease**    |                      |                                             |                                             |         |
|                      | 6/270(2.3%)          | 0/78 (0%)                                   | 6/192 (3.1%)                               | 0.288   |
| **Mild**             |                      |                                             |                                             |         |
|                      | 5/270 (1.9%)         | 0/78 (0%)                                   | 5/192 (2.6%)                               |         |
| **Moderate / severe**|                      |                                             |                                             |         |
|                      | 1/270 (0.4%)         | 0/78 (0%)                                   | 1/192 (0.5%)                               |         |
| **HIV or AIDS**      | 1/271 (0.3%)         | 0/77 (0%)                                   | 1/194 (0.5%)                               | 0.528   |
| **Cancer**           | 53/269 (19.7%)       | 13/77 (16.9%)                               | 40/192 (20.8%)                              | 0.042   |
| **Solid tumour**     | 51/269 (19%)         | 11/77 (14.3%)                               | 40/192 (20.8%)                              |         |
| **Metastatic**       | 2/269 (0.7%)         | 2/77 (2.6%)                                 | 0/192 (0%)                                 |         |
| **Haematological malignancy** | 4/269 (1.5%) | 0/78 (0%)                                   | 4/191 (2.1%)                               | 0.198   |
| **Connective tissue disease** | 21/273 (7.7%) | 4/77 (5.2%)                                 | 17/196 (8.7%)                              | 0.332   |
| **Peptic ulcer**     | 6/271 (2.2%)         | 2/77 (2.6%)                                 | 4/194 (2.1%)                               | 0.787   |
| **Charlson Comorbidity Index, median (range)** | 5.3 (0–15) (n = 219) | 5.3 (0–15) (n = 69) | 5.3 (0–12) (n = 150) | 0.938   |
| **Medication**       |                      |                                             |                                             |         |
| Angiotensin receptor blockers | 186/272 (68.4%) | 50/78 (64.1%)                               | 136/194 (70.1%)                             | 0.336   |
| Diuretics            | 92/269 (34.2%)       | 25/76 (32.9%)                               | 67/193 (34.7%)                              | 0.777   |
| Beta blockers        | 130/272 (47.8%)      | 38/78 (48.7%)                               | 92/194 (47.4%)                              | 0.847   |
| Calcium channel blockers | 105/272 (38.6%) | 25/78 (32.1%)                               | 80/194 (41.2%)                              | 0.159   |
| Vitamin D / alfacalcidol | 151/271 (55.7%) | 39/78 (50.0%)                               | 112/193 (58.0%)                             | 0.228   |
| Erythropoetin         | 19/272 (6.5%)        | 4/78 (5.1%)                                 | 15/194 (7.7%)                               | 0.446   |
| Phosphate binders    | 10/272 (3.7%)        | 0/78 (0%)                                   | 10/194 (5.2%)                               | 0.041   |
| Immunosuppressive drugs | 67/300 (22.3%) | 0/78 (0%)                                   | 67/222 (30.2%)                              | < 0.001 |

1 Glomerular diseases include: glomerulonephritis, nephrotic syndrome (any cause), glomerular proteinuria or haematuria (without biopsy), IgA nephropathy
2 Systemic diseases include: systemic lupus erythematosus, vasculitis, sarcoidosis
3 Other causes include: postrenal cause, renal artery stenosis, cancer (treatment)
± = standard deviation

Prerequisites for implementation in practice
A number of conditions must be met before patients can be referred back to primary care. First of all, the quality of care (QoC) for patients with CKD in primary care must be guaranteed. Some studies indicated that the QoC for these patients received solely from a GP is suboptimal [12, 13], while others have shown that GPs deliver an appropriate quality of care for patients referred back to primary care, in terms of periodic renal monitoring, preventing the deterioration of kidney function and maintaining blood pressure within an appropriate range [14, 15]. GPs recognition of patients with CKD in primary care and receiving co-management assistance from nephrologists, are both factors associated with improved QoC [13]. Our previous study shows that not all patients indicated for nephrologist care, actually receive nephrologist consultation or co-management. In addition, for patients aged 80 and older, it was questionable whether management by nephrologists contributes to a better clinical outcome [16]. To enhance the QoC in primary care, we believe it would be helpful to embed CKD care within the care of other chronic conditions to guarantee a periodic follow up [17]. Furthermore, to overcome other doubts about QoC in the primary care setting, we recommend the provision of care according
to a shared care model. The co-management of patient care by nephrologists and GPs led to the increased monitoring of eGFR, urine albumin and metabolic parameters, and resulted in more prescriptions of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers [18]. Shared care models for chronic conditions are predominantly found to have a positive effect [19–21]. Combining shared care with information technology such as a pop-up in medical records for recognising CKD, decision support in medical records or a web-based consultation system could also enhance QoC [22, 23].

Second, for the interdisciplinary management of patients, it is essential to make agreements on the tasks, responsibilities and communication between GPs and nephrologists. Not all professionals in the field will have the same expectations, as even among nephrologists there are different views about various tasks [24]; therefore, agreements should preferably be made regionally to ensure the close communication of GPs and nephrologists and to make use of a pre-existing collaborative relationships. A shared clinical information system could also facilitate better communication between primary and secondary care [25].
literature reveals that both GPs and nephrologists prefer shared care [26, 27], but only when sufficient information exchange is provided [24, 28]. GPs have said that, besides conservative care for older and frail patients with advanced CKD, they have little experience in treating patients with advanced CKD and welcome guidance from nephrologists [29]. Several studies have already been executed to improve co-ordination between primary and secondary care; for example, researchers introduced a kidney failure risk equation, which is a predictive model to determine whether care by a nephrologist is required, based on the patient’s risk for kidney failure [30, 31]. A predictive model alone is not sufficient for the co-ordination of CKD care between primary and secondary practices, however our BR criteria could also contribute to personalised decision making.

Last but not least, it is important to know whether patients are willing to be referred back to primary care. Not much has been written about this, despite patient willingness being a prerequisite for back referral. One study found that patients prefer to receive care from their GP, provided that GPs have access to a specialist for consultation or a system in which diagnostic procedures are organised by a specialist with patients subsequently being referred back to the GP for care [26]. Patients views and experiences concerning CKD care still need to be explored in more detail.

**Advice for further research**

Future research should focus on the actual implementation of the referral of patients with CKD back to primary care. The enabling and disabling factors need to be further explored, taking into account the opinions of patients, GPs and nephrologists. We didn’t study the underlying motives for push and pull factors among GPs and specialists. This also would require additional qualitative research. Further studies on supportive measures, such as ICT and health apps, are needed. In addition, it is very important to investigate the sustainability of back referrals and intervene on aspects that deviate from the intentions of the initial criteria. This could lead to changes in criteria or to extra interventions that support the referral back to primary care. Some stakeholders may ask for studies on the (cost-)effectiveness of back referrals.

**Strengths and limitations**

To our knowledge, this is the first study in which the criteria for back referrals for patients with CKD have been explicitly formulated. We decided to take a regional approach by inviting eight nephrologists from different hospitals (general and academic) and two GPs, all from the southeast of the Netherlands, to identify the criteria for back referrals. This interdisciplinary approach was intended to ensure that these criteria resulted in a longer-lasting working relationship to

| Kidney function eGFR | Albumin to creatinine ratio (mg/mmol) | Total |
|----------------------|--------------------------------------|-------|
|                      | A1 <3  | A2 <30 | A3 >30 |       |
| G1 >90               | 2 (2.6%) | 3 (3.8%) |       | 5 (6.4%) |
| G2 60–89             | 2 (2.6%) | 6 (7.7%) | 3 (3.8%) | 11 (14.1%) |
| G3a 45–59            | 6 (7.7%) | 8 (10.3%) | 3 (3.8%) | 17 (21.7%) |
| G3b 30–44            | 5 (6.4%) | 13 (16.0%) | 10 (12.8%) | 28 (35.9%) |
| G4 15–29             |       | 11 (14.1%) | 6 (7.7%) | 17 (21.8%) |
| G5 < 15              |       |       |       |       |
| Total                | 15 (19.2%) | 41 (52.6%) | 22 (28.2%) | 78 (100%) |

Different colours denote different levels of risk for cardiovascular events, progression to end-stage renal failure and mortality: green: low risk; yellow: moderately increased risk; orange: high risk; red, very high risk. Classification according to the Kidney Outcomes Quality Initiative guidelines (KDOQI).
provide the trust needed for a nephrologist to refer a patient back to primary care. The consensus process could have involved more than two GPs, but as the referral back should be initiated by nephrologists, we considered this to be an adequate balance. In addition, the recently developed transmural guideline supported the consensus process [32]. Other potential limitations exist in this work. We only reviewed the records of patients under nephrologist care, but patients with CKD who are treated by a general internist would likely also meet the BR criteria and could be included in future studies. We tried to avoid selection bias by instructing the nephrologists to invite all patients to participate in this study; nevertheless, we cannot fully exclude the possibility that selection bias may have occurred.

Conclusion
Taking the starting point that patients with less-progressive moderate or even stable advanced CKD can be managed in primary care, we developed criteria for back referrals. When applying these BR criteria to patients with CKD in outpatient clinics, a substantial proportion of patients turned out to be eligible for referral back to primary care. These patients often had cardiovascular comorbidities, and their renal care could therefore constitute part of a chronic care programme managed by their GP. Given the nature of CKD, such a programme would require a strong shared-care identity, supported by consultations between GPs and nephrologists. Future research should focus on the feasibility of actually implementing referrals back to primary care, the follow up of renal function in such a setting, and patient satisfaction with care.

Abbreviations
ADPKD: Autosomal dominant polycystic kidney disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; CWH: Canisius Wilhelmina Hospital; eGFR: Estimated glomerular filtration rate; GP: General practitioner; HIV / AIDS: Human immunodeficiency virus / acquired immunodeficiency syndrome; BR criteria: Back referral criteria; RRT: Renal replacement therapy; RUUMC: Radboud university medical center; SD: Standard deviation; TIA/CVA: Transient ischaemic attack / Cerebrovascular accident; VMC: VieCurie Medical Center

Acknowledgements
We thank all the participating patients from Radboud university medical center, Canisius Wilhelmina Hospital and VieCurie Medical Center. We also thank the participating nephrologists for their contributions to the formulation of the criteria for referral from secondary care back to primary care: M. Bleeker MD, PhD from Bernhoven Hospital Uden, J. Hofstra MD, PhD from Gelderse Vallee Hospital Ede, J. Huissen MD and C. de Bruin MD from Slingeland Hospital Doetinchem, and W. van Kuijk MD, PhD from VieCurie Medical Center Venlo.

Prior presentations
None.

Authors’ contributions
All authors read and approved the final manuscript. CvD organised the consensus meeting, collected and analysed the data and wrote the article. DvD collected data and wrote the article. WdG submitted the application, supervised CvD, participated in the consensus meeting, gave feedback on the article. MtD participated in the consensus meeting, facilitated the research in the Canisius Wilhelmina Hospital and gave feedback on the article. MH participated in the consensus meeting, facilitated the research in the VieCurie Medical Center and gave feedback on the article. WA was involved in the design of the study and wrote the article. NS submitted the application, supervised CvO, participated in the consensus meeting, gave feedback on the article. JW was involved in the design of the study, participated in the consensus meeting, facilitated the research in the Radboud university medical center and gave feedback on the article.

Funding
The Dutch Kidney Foundation funded this study (grant no. 1344D302).

Availability of data and materials
The dataset analysed during the current study is available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate
Ethical approval for this study was waived by the Medical Research Ethics Committee of Arnhem/Nijmegen, registration number 2017–3951. VieCurie Medical Center (report number 357) and Canisius Wilhelmina hospital (report number 024–2018) management separately gave their permission for this study to be conducted in their hospitals.

Competing interest
We have no conflicts of interest.

Consent for publication
Not applicable.

Author details
1. Department of Primary and Community Care, Radboud Institute for Health Sciences, Radboud university medical center, Geert Grootplein Noord 2, postal route 117, 6525 EZ, Nijmegen, The Netherlands. 2. Department of Internal medicine, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands. 3. Department of Internal medicine, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands. 4. Department of Nephrology, Radboud Institute for Health Sciences, Radboud university medical center, Geert Grootplein Zuid 8, postal route 464, 525, GA, Nijmegen, The Netherlands.

Received: 12 January 2021 Accepted: 13 April 2021
Published online: 19 May 2021

References
1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2012;2013(3):S1–150.
3. Nederlands huisartsen genootschap. NHG – Standaard Chronische nierziekten. Huisarts en Wetenschap, 2018.
4. NICE Clinical guideline: Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. London: National Collaborating Centre And National Institute for Health and care Excellence; 2008 September (last modified 2014, July).
5. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124(11):1073–80 e2. https://doi.org/10.1016/j.amjmed.2011.04.026.
6. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lanec. 2013;382(9889):339–52. https://doi.org/10.1016/S0140-6736(13)60695-4.
7. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47. https://doi.org/10.1001/jama.298.17.2038.
8. Singh K, Waikar SS, Samal L. Evaluating the feasibility of the KDIGO CKD referral recommendations. BMC Nephrol. 2017;18(1):223. https://doi.org/10.1186/s12882-017-0646-y.

9. Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393–409. https://doi.org/10.1038/nrneph.2017.63.

10. Coresh J. Update on the burden of CKD. J Am Soc Nephrol. 2017;28(4):1020–2. https://doi.org/10.1681/ASN.2016213174.

11. Castor EDC. https://www.castoredc.com/.

12. Van Gelder VA, Scherbier-de Haan ND, De Grauw WJ, Vervoort GM, Van Weel C, Beemans MC, et al. Quality of chronic kidney disease management in primary care: a retrospective study. Scand J Prim Health Care. 2016;1–8.

13. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;26(4):386–92. https://doi.org/10.1007/s11606-010-1523-6.

14. Meran S, Don K, Shah N, Donovan K, Riley S, Phillips AO. Impact of chronic kidney disease management in primary care. QJM. 2011;104(1):27–34. https://doi.org/10.1093/qjmed/hcq151.

15. Stevens KK, Woo YM, Rodger RS, Geddes CC. Discharging patients from the nephrology clinic to primary care--will they get appropriate monitoring of renal function? QJM. 2009;102(6):425–8. https://doi.org/10.1093/qjmed/hcp400.

16. McClure M, Jorna T, Wilkinson L, Taylor J. Elderly patients with chronic kidney disease: do they really need referral to the nephrology clinic? Clin Kidney J. 2017;10(5):698–702. https://doi.org/10.1093/ckj/sfx034.

17. van Dipten C, van Berkel S, van Gelder VA, Wetzels JF, Akkermans RP, de Grauw WJ, et al. Adherence to chronic kidney disease guidelines in primary care patients is associated with comorbidity. Fam Pract. 2017;34(4):459–66. https://doi.org/10.1093/fampra/cmw002.

18. Samal L, Wright A, Waikar SS, Linder JA. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis. BMC Nephrol. 2015;16(1):162. https://doi.org/10.1186/s12882-015-0154-x.

19. Scherbier-de Haan ND, Vervoort GM, van Weel C, Braspennin HC, Mulder J, Wetzels JF, et al. Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial. Br J Gen Pract. 2013;63(617):98–106. https://doi.org/10.3399/bjp.2013x675386.

20. Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis. 2006;47(1):103–14. https://doi.org/10.1053/j.ajkd.2005.09.020.

21. Dean J. Organising care for people with diabetes and renal disease. J Ren Care. 2012;38(Suppl 1):23–9. https://doi.org/10.1111/j.1755-6686.2012.00272.x.

22. Major RW, Brown C, Shepherd D, Rogers S, Pickering W, Warwick GL, et al. The primary-secondary care partnership to improve outcomes in chronic kidney disease (PSP-CKD) study: a cluster randomized controlled trial in primary care. J Ren Care. 2019;35(7):1261–70. https://doi.org/10.1681/ASN.201810042.

23. van Gelder VA, Scherbier ND, van Berkel S, Akkermans RP, De Grauw IS, Adang EM, et al. Web-based consultation between general practitioners and nephrologists, a cluster randomized controlled trial. Fam Pract. 2017;34(4):430–6. https://doi.org/10.1093/fampra/cmx131.

24. Haase A, Stracke S, Chenot JF, Weckmann G. Nephrologists’ perspectives on ambulatory care of patients with non-dialysis chronic kidney disease - a qualitative study. Health Soc Care Community. 2019;27(4):e438–e48. https://doi.org/10.1111/hsc.12744.

25. Garcia Garcia M, Valenzuela Mujica MP, Martinez Ocana JC, Otero Lopez MD, S. Ponz Clemente E, Lopez Alba T, et al. results of a coordination and shared clinical information programme between primary care and nephrology. Nefrologia. 2011;31(1):184–90. https://doi.org/10.3265/Nefrologia.pre2010Oct10615.

26. Wilson C, Campbell SM, Luker KA, Caress AL. Referral and management options for patients with chronic kidney disease: perspectives of patients, generalists and specialists. Health Expect. 2015;18(3):325–34.

27. Diamantidis CJ, Powe NR, Jaar BG, Greer RC, Troll MU, Bouvarele L. Primary care-specialist collaboration in the care of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):334–43. https://doi.org/10.2215/CJN.06240710.

28. Greer RC, Liu Y, Cavanaugh K, Diamantidis CJ, Estrella MM, Sperati CJ, et al. Primary care physicians’ perceived barriers to nephrology referral and co-management of patients with CKD: a qualitative study. J Gen Intern Med. 2019;34(7):1228–35. https://doi.org/10.1007/s11606-019-04975-y.

29. Tonkin-Crine S, Santer M, Leydon GM, Murtagh FE, Farthing K, Caskey F, et al. GPS’ views on managing advanced chronic kidney disease in primary care: a qualitative study. Br J Gen Pract. 2015;65(636):e469–77. https://doi.org/10.3399/bjgp15X685693.

30. Smekal MD, Tam-Tham H, Finlay J, Donald M, Benterud E, Thomas C, et al. Perceived benefits and challenges of a risk-based approach to multidisciplinary chronic kidney disease care: a qualitative descriptive study. Can J Kidney Health Dis. 2018;5:2054358118763809.

31. Bhachu HK, Cockwell P, Subramanian A, Nirantharakumar K, Kyte D, Calvert M. Cross-sectional observation study to investigate the impact of risk-based stratification on care pathways for patients with chronic kidney disease: protocol paper. BMJ Open. 2019;9(6):e027315. https://doi.org/10.1136/bmjopen-2018-027315.

32. Federatie medisch specialisten. Multidisciplinaire richtlijn Chronische nierzonde. 2018. https://richtlijnendatabase.nl/richtlijn/chronische_nierschade_de_cns/startpagina_-_chronische_nierschade_cns.html.